Protara Therapeutics to Host Conference Call and Webcast to Review New Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Naïve NMIBC Patients on Wednesday, December 3, 2025

Core Insights - Protara Therapeutics, Inc. is hosting a conference call and live webcast on December 3, 2025, to discuss new data from an interim analysis of the Phase 2 ADVANCED-2 trial of TARA-002 for non-muscle invasive bladder cancer [1] - The data will be presented at the 26th Annual Meeting of the Society of Urologic Oncology, along with updates on FDA feedback regarding the registrational path for TARA-002 [1] Company Overview - Protara Therapeutics is a clinical-stage biotechnology company focused on developing transformative therapies for cancer and rare diseases [3] - The lead candidate, TARA-002, is an investigational cell-based therapy aimed at treating non-muscle invasive bladder cancer and lymphatic malformations [3] - Protara is conducting a Phase 2 trial for TARA-002 in NMIBC patients who are unresponsive or naïve to Bacillus Calmette-Guérin treatment, as well as a Phase 2 trial in pediatric patients with lymphatic malformations [3] - The company is also developing IV Choline Chloride, a phospholipid substrate replacement for patients on parenteral nutrition [3]